TY - JOUR T1 - The basic reproduction number of SARS-CoV-2: a scoping review of available evidence JF - medRxiv DO - 10.1101/2020.07.28.20163535 SP - 2020.07.28.20163535 AU - Ann Barber AU - John Griffin AU - Miriam Casey AU - Áine B. Collins AU - Elizabeth Ann Lane AU - Quirine Ten Bosch AU - Mart De Jong AU - David Mc Evoy AU - Andrew W. Byrne AU - Conor G. McAloon AU - Francis Butler AU - Kevin Hunt AU - Simon J. More Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/30/2020.07.28.20163535.abstract N2 - Background The transmissibility of SARS-CoV-2 determines both the ability of the virus to invade a population and the strength of intervention that would be required to contain or eliminate the spread of infection. The basic reproduction number, R0, provides a quantitative measure of the transmission potential of a pathogen.Objective Conduct a scoping review of the available literature providing estimates of R0 for SARS-CoV-2, provide an overview of the drivers of variation in R0 estimates and the considerations taken in the calculation of the parameter.Design Scoping review of available literature between the 01 December 2019 and 07 May 2020.Data sources Both peer-reviewed and pre-print articles were searched for on PubMed, Google Scholar, MedRxiv and BioRxiv.Selection criteria Studies were selected for review if (i) the estimation of R0 for SARS-CoV-2 represented either the initial stages of the outbreak or the initial stages of the outbreak prior to the onset of widespread population restriction (“lockdown”), (ii) the exact dates of the study period were provided and (iii) the study provided primary estimates of R0.Results A total of 20 R0 for SARS-CoV-2 estimates were extracted from 15 studies. There was substantial variation in the estimates reported. Estimates derived from mathematical models fell within a wider range of 1.94-6.94 than statistical models which fell between the range of 2.2 to 4.4. Several studies made assumptions about the length of the infectious period which ranged from 5.8-20 days and the serial interval which ranged from 4.41-14 days. For a given set of parameters a longer duration of infectiousness or a longer serial interval equates to a higher R0. Several studies took measures to minimise bias in early case reporting, to account for the potential occurrence of super-spreading events, and to account for early sub-exponential epidemic growth.Conclusions The variation in reported estimates of R0 reflects the complex nature of the parameter itself, including the context (i.e. social/spatial structure), the methodology used to estimate the parameter, and model assumptions. R0 is a fundamental parameter in the study of infectious disease dynamics, however it provides limited practical applicability outside of the context in which it was estimated, and should be calculated and interpreted with this in mind.STRENGTHS AND LIMITATIONS OF THE SCOPING REVIEWThis study provides an overview of basic reproduction number estimates for SARS-CoV-2 across a range of settings, a fundamental parameter in gauging the transmissibility of an emerging infectious disease.The key drivers of variation in R0 estimates and considerations in the calculation of the parameter highlighted across the reviewed studies are discussed.This evidence may be used to help inform modelling studies and intervention strategies.Given the need for rapid dissemination of information on a newly emerging infectious disease, several of the reviewed papers were in the pre-print phase yet to be peer-reviewed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll investigators are full-time employees (or retired former employees) of Wageningen University, University College Dublin or the Irish Department of Food and the Marine (DAFM). No additional funding was obtained for this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A ER -